Reports Q3 revenue $60.2M, consensus $55.1M. “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Furthermore, hospital demand for INTERCEPT fibrinogen complex or IFC in the U.S. continues to increase, bolstered by the many positive case studies from large academic hospitals that have implemented IFC in routine use,” said William “Obi” Greenman, Cerus (CERS)’ president and chief executive officer.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERS:
- CERS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cerus Corporation’s New Study on Trauma Hemorrhage Treatment: A Potential Game Changer?
- Cerus Corporation: Buy Rating Highlighted by Growth Potential and Undervaluation
- Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease
- Cerus Corporation’s New Study on INTERCEPT RBCs: Potential Market Impact